News

  • 8 November 2007
    Novexel raises € 50 million in a series B round

    Novexel, the specialty pharmaceutical company focused on the discovery and development of novel antibacterials and anti-fungals, today announces that it has raised €50 million in a Series B fundraising. The round was led by new investor, Edmond de Rothschild Investment Partners of Paris and included participation from all Novexel’s existing investors (Atlas Venture, Sofinnova, Abingworth, 3i, Novo A/S and BIT), as well as other new investors, Goldman Sachs, NeoMed and NIF SMBC (Tokyo). The funding is the largest raised by a private European company in this sector in the last twelve months.

  • 23 August 2007
    EUSA Pharma acquires Innocoll's antibiotic and pain control products

    EUSA Pharma Inc (“EUSA"), a transatlantic specialty pharmaceutical company focused on oncology, pain control and critical care, today announced the acquisition of the assets of Innocoll Inc ('Innocoll'). 

  • 27 June 2007
    PregLem announces CHF 32 million Series A funding from leading European VC firms and license agreement with Ipsen

    PregLem today announced the closing of a CHF 32 million Series-A financing round (€20 million). The Series A financing round was led by Sofinnova Partners, and co-led by NeoMed Management and MVM Life Science Partners LLP. Concurrently, PregLem signed a licensing agreement with Ipsen (Euronext: IPN) under which Ipsen will grant PregLem worldwide development and commercialization rights to certain Ipsen compounds, for use in reproductive medicine only. The details of the agreement are not being disclosed. The funding will allow PregLem to undertake the development of these and other key compounds in the PregLem portfolio.

  • 1 March 2007
    EUSA Pharma raises USD 175 million for acquisition of OPi SA and further development of the Company

    EUSA Pharma announces the agreed acquisition of OPi SA (“OPi”), an integrated biopharmaceutical company. The acquisition will create a strong platform on which to build a significant transatlantic business. The acquisition is being funded with finance from a syndicate led by Essex Woodlands and 3i including, Goldman Sachs, advent Venture Partners, NeoMed and NovaQuest.

  • 3 November 2006
    Santhera prices IPO at CHF 90 per share and raises CHF 88.5 million

    Santhera Pharmaceuticals, a Swiss specialty pharmaceutical company with a focus on neuromuscular diseases, today announced that it has successfully completed its Initial Public Offering (IPO) of shares and its listing on the SWX Swiss Exchange.